StreetAlpha.app
Home › Stocks › ELOX

Eloxx Pharmaceuticals, Inc. (ELOX)

$11.74
▼ −7.92%
LAST CLOSE · NOV 17

Eloxx Pharmaceuticals develops drug candidates for rare genetic kidney and dermatologic diseases. It last closed at $11.74 on Nov 17, down 7.92% on the day. ELOX reports earnings on Fri, Feb 12, 2027. The average 12-month price target from 3 analysts is $36.67 (+212.3% from the last close), with a high of $40.00 and a low of $32.00. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell).

AI Auto Pilots
Is ELOX in one of our four AI portfolios? Sign in free to see

Key Stats

Fiscal 2025
Results
Revenue
$0
−100.0% vs a year ago
Net income
−$6.0M
EPS (diluted)
−$0.49
Valuation
Market cap
$48.0M
4.1M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$56.3M
At Sep 30
Debt
$1.0M
At Dec 31
Shareholder equity
$41.1M
Shares outstanding
4.1M
At Nov 9
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2023: $0$0FY2023FY2024: $6.4M$6.4MFY2024FY2025: $0$0FY2025

From ELOX's SEC filings, latest 10-Q for the period ending Dec 31, 2025 (filed Nov 16).

Next report
Feb 12
2027 · Time not announced
Consensus EPS forecast
-$0.59
$1.8M revenue est.
Year-ago EPS
—
Not on file
Options-implied move
—
Posted about a week before
Analyst consensus
Strong Buy
Based on 3 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
3firms
3 Buy0 Hold0 Sell
Each firm's latest rating on ELOX in the past 90 days
Average 12-month target
$36.67
▲ 212.3% upside

Based on 3 analysts who set a price target on ELOX in the past 90 days. The average target is $36.67, with a high of $40.00 and a low of $32.00, compared with the last close of $11.74.

Low $32.00Avg $36.67High $40.00
Blue marker: last close $11.74
Highest target$40.00
Average target$36.67
Lowest target$32.00
Latest rating changes
GuggenheimTarget lowered
Oct 28Buy$43 → $40
Leerink PartnersInitiated
Sep 18Buy$32
LUCID CAPITAL MARKETSInitiated
Aug 20Buy$38
LifeSci CapitalInitiated
Jul 22Buy$40
GuggenheimInitiated
Jul 20Buy$43
DateFirmActionRatingPrice target
Oct 28GuggenheimTarget loweredBuy$43 → $40
Sep 18Leerink PartnersInitiatedBuy$32
Aug 20LUCID CAPITAL MARKETSInitiatedBuy$38
Jul 22LifeSci CapitalInitiatedBuy$40
Jul 20GuggenheimInitiatedBuy$43
Loading…

Technical Analysis

ELOX · as of the Nov 17 close · updated after every close
Falling, nearing oversold

The stock is 11% below its 20 day and 22% below its 50 day average. Momentum is fading (RSI 36), near oversold. The nearest support is the swing low (Nov 9) at $11.66, and the nearest resistance the Pivot at $12.09.

Short trendBearish
Long trendNot enough history
MomentumFading
StretchNear oversold
VolatilityLow, 9.9%/day
Key levels
$23.4052 week high+99.3%
$14.73100 day average+25.5%
$14.3750 day average+22.4%
$13.78Swing high (Nov 9)+17.4%
$12.9820 day average+10.6%
$12.63Pivot R1+7.6%
$12.09Pivot+3.0%
$11.74Last close
$11.66Swing low (Nov 9)−0.7%
$11.19Pivot S1−4.7%
$8.2052 week low−30.2%
Indicators
RSI (14)36.15Weak, oversold below 30Neutral
MACD-0.45Above its signal lineBullish
Stochastic39.9Middle of its rangeNeutral
ADX (14)22.9Weak trend
Williams %R-91.1Oversold below −80, overbought above −20Oversold
CCI (20)-252.3Oversold below −100, overbought above 100Oversold
Rate of change−9.1%Change over 10 sessionsBearish
ATR (14)$1.17Typical daily range, 9.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200–
What happened before, for ELOX

What happened before

See how ELOX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Whale Options Flow

90D

No whale options trades in ELOX in the last 90 days.

Loading…

See today’s whale options flow across the market →

ELOX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ▼6 buying vs 7 selling
  • ▼Held by funds -4.9 pts
  • ▼Funds holding -2
  • ●No superinvestor moves
  • ●Put/call not meaningful
Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding2022−9.1%
In funds' top 10110.0%
Held by funds66.1%71.0%−4.9 pts
New / increased3 / 322 / 0−72.7%
Reduced / sold out2 / 50 / 0–
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ELOX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ELOX is in one of them and how their past ELOX trades turned out.

ELOX in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ELOX in an article yet. Here's the latest on the wider market.

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals is a drug development company based in Arlington, Massachusetts. It is developing product candidates for rare genetic kidney and dermatologic diseases, with an approach that targets processes such as fibrosis, inflammation and proteinuria. Its candidates are still in development. If approved, they would be prescribed to patients by physicians.

Headquarters
Arlington, MA